The enhanced in vivo (1.6 times higher 1 h after injection) and ex vivo (1.9 times higher) tumour uptake of the iNGR derivative is consistent with previous research, where the two-fold higher cellular uptake ratio of the dual-modified liposomes was due to attachment to NRP-1 [69]. Here, NRP1 is linked to neoplasm.